Артериальная гипертензия: портретная галерея 18-20 веков

рекомендации, артериальная гипертензия, комбинированная терапия

1. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. - 2009. - Vol. 27, № 11. - P. 2121-2158.

2.

3. Khoo C.M <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_AbstractPlus&term=%22Khoo+CM%22%5BAuthor%5D>., Liew C.F., Chew S.K., Tai E.S. The impact of central obesity as a prerequisite for the diagnosis of metabolic syndrome // Obesity (Silver Spring). <javascript:AL_get(this,%20'jour',%20'Obesity%20(Silver%20Spring).');> - 2007. - Vol. 15, № 1. - P. 262-269.

4.

5. Julius S., Valentini M., Palatini P. Overweight and hypertension: a 2-way street? // Hypertension. - 2000. - Vol. 35, № 3. - P. 807-813.

6.

7. Julius S. Sympathetic overactivity and insulin resistance in hypertension // SNS Report. - 2000. - Vol. 1. - P. 2-3.

8.

9. Kaaja J., Poyhonen-Alho M.K. Insulin resistance and sympathetic overactivity in women // J. Hypertens. - 2006. - Vol. 24, № 1. - P. 131-141.

10.

11. Turnbull F., Woodward M., Neal B. et al. Blood pressure lowering treatment Trialists' Collaboration. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials // Eur. Heart J. - 2008. - Vol. 29, № 21. - P. 2669-2680.

12.

13. Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2049-2051.

14.

15. Bramlage P., Thoenes M., Kirch W. et al. Clinical practice and recent recommendations in hypertension management: reporting a gap in a global survey of 1259 primary care physicians in 17 countries // Curr. Med. Res. Opin. - 2007. - Vol. 23, № 4. - P. 783-791.

16.

17. Hasford J., Mimran A <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mimran%20A%22%5BAuthor%5D>., Simons W.R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Simons%20WR%22%5BAuthor%5D>. A population-based European cohort study of persistence in newly diagnosed hypertensive patients // J. Hum. Hypertens. - 2002. - Vol. 16, № 8. - P. 569-575.

18.

19. Elliott W.J., Meyer P.M. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis [abstract] // J. Clin. Hypertens. (Greenwich). - 2007. -Vol. 9. - P. A33.

20.

21. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients: HOPE (Heart Outcomes Prevention Evaluation Study) // N. Engl. J. Med. - 2000. - Vol. 342, № 3. - P. 145-153.

22.

23. Telmisartan, Ramipril, or both in patients at high risk for vascular events. The ONTARGET Investigators // N. Engl. J. Med. - 2008. - Vol. 358, № 15. - P. 1547-1559.

24.

25. Elliot W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369, № 9557. - P. 201-207.

26.

27. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. - 2003. - Vol. 115, № 1. - P. 41-46.

28.

29. Elliott W.J., Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis // Lancet. - 2007. - Vol. 369, № 9557. - P. 201-207.

30.

31. Jaillard J., Rouffy J., Sauvanet J. et al. Long-term influence of betaxolol on plasma lipids and lipoproteins // In L.E.R.S. Monograph / Ed. by New York, Raven Press, 1983. - P. 221-231

32.

33. Van Os, Van Brummeneisen P., Woitteis A.J.J. Betaxolol on obese hypertensive patients. Long-term effects on blood pressure and serum lipids // Neth. J. Med. - 1991. - Vol. 40. - P. 227-231.